 NEW YORK, Jan. 27, 2021 GLOBE NEWSWIRE -- Intercept Pharmaceuticals, Inc. Nasdaq:ICPT, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the listing of Intercepts product on the U.S. Food and Drug Administration FDA Adverse Event Reporting System FAERS website reached a conclusion regarding the status of a newly identified safety signal NISS for Ocaliva obeticholic acid that the Company believes is incorrect. 